{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-060130","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.163375+00:00","generated_at":"2026-06-15T01:02:45.739443+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Leap Therapeutics Q1 net loss $41.9M on $29.6M IPR&D charge; cash $102M","bullets":["Net loss $41.9M ($10.4M Q1'22); includes $29.6M IPR&D charge from Flame acquisition.","R&D expense $38.9M, G&A $3.8M; cash $102.0M at Mar 31, 2023.","Completed Part A enrollment in Phase 2 DeFianCe study of DKN-01 in CRC; initial data mid-2023.","Acquired Flame Biosciences, adding anti-Claudin18.2 candidate FL-301 and ~$50M cash.","Will present updated long-term data from DisTinGuish study in GEA at ASCO June 5, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-060130","json":"https://secwatch.observer/filing/0001104659-23-060130.json","markdown":"https://secwatch.observer/filing/0001104659-23-060130.md","text":"https://secwatch.observer/filing/0001104659-23-060130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923060130/0001104659-23-060130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923060130/tm2315622d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:02:45.739443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"811ced1db3b4cba29b4bb406ee52768368cbdc45","claim":"CYPHERPUNK TECHNOLOGIES INC. reported first quarter ended March 31, 2023 results: net income Net Loss was $41.9 million.","evidence_excerpt":"On May 15, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923060130/0001104659-23-060130-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net Loss was $41.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}